![Pierre-Olivier Goineau](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Pierre-Olivier Goineau
Président chez
Goineau Développement & Finance SASU
Profil
Pierre-Olivier Goineau was the founder of ERYTech Pharma SA, founded in 2004, holding the title of Vice Chairman, Co-COO & Head-Investor Relations from 2013 to 2015.
Mr. Goineau was the founder of StromaCare SAS, founded in 2020, holding the title of Chief Executive Officer.
Current jobs include Chairman at Goineau Développement & Finance SASU since 2015, Senior Venture Partner at Sofimac Innovation SAS since 2013, Manager at SCI Du Grand Tambour, and President-Supervisory Board at NEURONAX SA. Former job includes Director at France Biotech Association.
Education includes a graduate degree from the University of Lyon.
Postes actifs de Pierre-Olivier Goineau
| Sociétés | Poste | Début |
|---|---|---|
SCI Du Grand Tambour | Corporate Officer/Principal | - |
Goineau Développement & Finance SASU
 Goineau Développement & Finance SASU Miscellaneous Commercial ServicesCommercial Services Provides business and management consulting services | Président | 02/04/2015 |
NEURONAX SA
 NEURONAX SA Pharmaceuticals: MajorHealth Technology Develops and provides drugs supporting neural repair to treat degenerative disorders of the central nervous system | Directeur/Membre du Conseil | - |
Sofimac Innovation SAS
 Sofimac Innovation SAS Investment ManagersFinance Sofimac Innovation is an active manager which prefers to invest equity to create or grow limited liability companies in the ICT sector. The firm invests principally in France and Western European countries because they believe that geographical proximity between investee companies and their team is necessary to provide effective support. Sofimac Innovation typically invests €0.5-€1.5 million in the first round in early-stage companies and €0.5-€3 million with co-investors in subsequent rounds when necessary. The firm works in partnership with their investee companies, providing expertise to support them in assessing and positioning their new technology in their competitive environment, measuring and developing the managing team's potential for success and building the foundations that will allow the company to transform the initial concept into reality. Sofimac Innovation aims to invest in companies which have a technological innovation with growth potential, a quality management team, technological intensity and barriers to entry (including intellectual property rights ownership), a large target market with significant growth potential, a robust marketing strategy and a project in its final stage of development. | Private Equity Investor | 01/11/2013 |
Anciens postes connus de Pierre-Olivier Goineau
| Sociétés | Poste | Fin |
|---|---|---|
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology Develops medicinal products for orphan oncology and rare diseases | Fondateur | 08/01/2015 |
StromaCare SAS
 StromaCare SAS Miscellaneous Commercial ServicesCommercial Services Engages in research and development of stroma | Directeur Général | - |
France Biotech Association
 France Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates an organisation for growth of health industry | Président | - |
Formation de Pierre-Olivier Goineau
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
23
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Sofimac Innovation SAS
Sofimac Innovation SAS Investment ManagersFinance Sofimac Innovation is an active manager which prefers to invest equity to create or grow limited liability companies in the ICT sector. The firm invests principally in France and Western European countries because they believe that geographical proximity between investee companies and their team is necessary to provide effective support. Sofimac Innovation typically invests €0.5-€1.5 million in the first round in early-stage companies and €0.5-€3 million with co-investors in subsequent rounds when necessary. The firm works in partnership with their investee companies, providing expertise to support them in assessing and positioning their new technology in their competitive environment, measuring and developing the managing team's potential for success and building the foundations that will allow the company to transform the initial concept into reality. Sofimac Innovation aims to invest in companies which have a technological innovation with growth potential, a quality management team, technological intensity and barriers to entry (including intellectual property rights ownership), a large target market with significant growth potential, a robust marketing strategy and a project in its final stage of development. | Finance |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology Develops medicinal products for orphan oncology and rare diseases | Health Technology |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates an organisation for growth of health industry | Commercial Services |
University of Lyon
 University of Lyon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SCI Du Grand Tambour | |
NEURONAX SA
NEURONAX SA Pharmaceuticals: MajorHealth Technology Develops and provides drugs supporting neural repair to treat degenerative disorders of the central nervous system | Health Technology |
Goineau Développement & Finance SASU
Goineau Développement & Finance SASU Miscellaneous Commercial ServicesCommercial Services Provides business and management consulting services | Commercial Services |
StromaCare SAS
StromaCare SAS Miscellaneous Commercial ServicesCommercial Services Engages in research and development of stroma | Commercial Services |
